SMAD4 as a Marker for Colorectal Cancer Treatment
Author Information
Author(s): J-L Boulay, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C
Primary Institution: University Hospital, Basel, Switzerland
Hypothesis
Does the deletion of the SMAD4 gene influence the outcome of patients with colorectal cancer receiving 5-fluorouracil-based chemotherapy?
Conclusion
Patients with normal SMAD4 gene copy status benefit more from 5-fluorouracil-based chemotherapy than those with SMAD4 deletion.
Supporting Evidence
- 67% of colorectal cancer patients had SMAD4 gene deletion.
- Patients with normal SMAD4 had a three-fold higher benefit from chemotherapy.
- Deletion of SMAD4 gene showed borderline significance in predicting treatment outcomes.
Takeaway
If a patient has a certain gene called SMAD4, they might do better with a specific cancer treatment than if they don't have that gene.
Methodology
Real-time quantitative PCR was used to determine gene copy alterations in colorectal tumor biopsies.
Limitations
The study is based on a subset of patients from a previous study, which may limit generalizability.
Participant Demographics
Patients were part of a previous randomized study of adjuvant chemotherapy for colorectal cancer.
Statistical Information
P-Value
0.045
Confidence Interval
95% CI=0.97–10.8
Statistical Significance
p=0.045
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website